Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: Risk of coexistent double cancer by Hidetaka Uramoto et al.
RESEARCH ARTICLE Open Access
Clinicopathological characteristics of resected
adenosquamous cell carcinoma of the lung:
Risk of coexistent double cancer
Hidetaka Uramoto1*, Sohsuke Yamada2, Takeshi Hanagiri1
Abstract
Background: adenosquamous carcinoma (ADSQ) of non-small cell lung cancer (NSCLC) is a rare disease and the
biological behavior and clinicopathological characteristics have not yet been thoroughly described.
Method: This study reviewed the patient charts of 11 (1.6%) ADSQ cases among 779 patients with primary lung
cancer who underwent a lung resection. The characteristics and clinicopathological factors were evaluated
retrospectively.
Results: Six of the 11 patients with ADSQ were male and five were female. The mean age was 67.3 years’ olds.
Three patients had pathological stage IA, one patient each had stage IB and IIA, five patients had stage IIIA, and
one patient stage IIIB. Five patients had coexistent double cancer including 2 gastric, 1 rectal, 1 prostate and
1 bladder cancer. ADSQ was found less frequently in males than squamous cell carcinoma (SQ). ADSQ was found
more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than
adenocarcinoma (AD). The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and
45.5%, respectively. ADSQ had a significantly correlation with double cancer (ADSQ vs. non- ADSQ p = 0.03). A
multivariate analysis showed no significant prognostic difference between the patients with ADSQ and non- ADSQ.
Conclusions: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD
and SQ. However, surgeons must be cautious of any coexistent double cancer because approximately half of all
patients with ADSQ of the lung have double cancer.
Introduction
Lung cancer remains the most common cause of cancer
death worldwide [1]. Despite recent improvements in
diagnostic technologies, more than 50% of patients pre-
sent locally advanced or distant metastatic disease, and
the prognosis still remains unsatisfactory [2,3]. One rea-
son for this is that the specific characterization of phe-
notype according to the pathological diagnosis has not
been clarified, especially with regard to minor pheno-
types, such as ADSQ [4] and large cell neuroendocrine
carcinoma [5]. There are few reports of the clinical sig-
nificance of ADSQ [6-9]. The effectiveness of surgical
resection of ADSQ of the lung remains poorly defined
because of the relatively low frequency of this type of
tumor [6,7]. Shimizu. et al. reported that the survival
rates for patients with ADSQ were statistically worse
than for patients with SQ and AD, due to the highly
aggressive pathological stage of ADSQ [7]. On the other
hand, Hsia et al. reported that the prognostic behavior
of ADSQ had no influence on survival in comparison to
the survival curves with those for SQ and AD [4] consis-
tent with previous reports [8,9]. Therefore, the prognos-
tic impact of ADSQ in lung cancer still remains
controversial. Furthermore, no series has addressed the
correlation between the ADSQ and coexistent double
cancer. This study retrospectively reviewed cases a 13-
year period to clarify the correlation between the ADSQ
and clinicopathological factors including coexistent dou-
ble cancer and to elucidate the prognostic significance
of ADSQ of the lung in comparison to the AD and SQ.* Correspondence: hidetaka@med.uoeh-u.ac.jp
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Materials and methods
Patients and methods
The characteristics and clinicopathological factors were
evaluated retrospectively. Seven hundred and seventy-
nine patients with primary lung cancer underwent a
surgical resection between April 1994 to March 2006 at
the Second Department of Surgery at University of Occu-
pational and Environmental Health, Kitakyushu, Japan.
Of these, 403, 187, 39, 24, 11, 125, and 10 patients were
diagnosed as AD, SQ, large cell carcinoma, small cell car-
cinoma, ADSQ, multiple primary lung cancer (MPLC),
and others, respectively. According to the established cri-
teria, on routine microscopic examination using hema-
toxylin and eosin staining, a sample from a tumor
containing at least 20% each of AD and SQ is classified
as ADSQ [10]. Specimens from each of these patients
were reviewed critically by one (S.Y.) pathologist. This
study evaluated 11 cases (1.6%) with ADSQ among 779
resected primary lung cancers. The characteristics of the
patients with ADSQ are shown in Table 1. They included
6 males and 5 females with a mean age of 67.3 years, ran-
ging in age from 48 to 79 years. Of these eleven patients,
all had undergone complete resections, and six were N0
cases. The pathological stages of the cancer were stage
IA in 3 patients, IB in 1, IIA in 1, IIIA in 5, IIIB in 1,
according to the TNM classification revised by the Inter-
national union Against Cancer [11]. Patients were fol-
lowed up with clinical assessments, chest X-rays, and
tumor marker every month during the first year and
every 3 months thereafter after operation. Computed
tomography, bone scintigram and brain magnetic reso-
nance imaging were all performed every 6 months. The
mean observation period was 46.1 months.
Statistical analysis
Statistical analyses were performed using the Stat view
5.0 software program for Windows (Abacus Concepts,
Inc., California). The chi-square test was used to assess
the relationship between ADSQ and each of the clini-
copathological features. In the prognostic analysis, the
Kaplan-Meier method was used to estimate the prob-
ability of survival, and survival differences were ana-
lyzed by the log-rank test. A multivariate analysis was
performed according to Cox’s proportional hazards
Table 1 Characteristics of the patients with ADSQ
Case Age Sex Symptom Smoking P-Stage operation Additional
treatment
1 61 M none current IIIA L carboplatin/paclitaxel
2 68 F cough, fever current IIIA L carboplatin/paclitaxel
3 62 M cough never IIIB P n.d.
4 72 F cough Formera IB L n.d.
5 77 F none current IA L n.d.
6 79 M none ever IA L n.d.
7 55 M cough current IA L n.d.
8 72 M none current IIIA L uracil and tegafur
9 74 F none never IIIA L radiation
10 72 M cough current IIA L n.d.
11 48 F hemosputum never IIIA L carboplatin/paclitaxel
Case Recurrence Chemotherapy for recurrence Disease free interval
(days)
Double ca Outcome Cause of death
1 + n.d. 204 - Dead Lung cancer
2 - - - - Alive -
3 - - - Prostate ca
**
Alive -
4 - - - Gastric ca** Alive -
5 - - - Gastric ca* Alive -
6 + n.d. 734 Bladder ca* Alive -
7 - - - - Alive -
8 + cisplatin/5-Fu 145 - Dead Lung cancer
9 + carboplatin/uracil and tegafur 101 - Dead Lung cancer
10 + n.d. 995 Rectal ca* Dead Lung cancer
11 + carboplatin/docetaxel®cisplatin/5-
Fu
192 - Dead Lung cancer
aFormer smokers are defined persons who stopped smoking more than 3 years previously. L: Lobectomy, P: Pneumonectomy. n.d: not done.
*Double cancer was detected before treatment of lung cancer. **It was done after that.
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model. A p-value less than 0.05 was considered to be
significant.
Results
The clinical features of ADSQ patients
The clinical features of the patients with ADSQ are
summarized in Table 1. The most frequent symptoms
were cough. They included 8 smokers and 3 never smo-
kers. Bronchoscopic examination indicated that the
tumor was centrally located in two cases and was per-
ipherally located in nine cases. All patients underwent
bronchoscopy, and the results of biopsy or cytology
revealed a malignancy in 7 (63.6%). The preoperative
pathological diagnosis was SQ in three patients, non-
small cell lung carcinoma in two patients and AD in
one patient. The preoperative cytological diagnosis with-
out definite pathological diagnosis was AD in one
patient. All patients underwent a lobectomy except for
one pneumonectomy. Five of 11 patients received post-
operative adjuvant therapy including chemotherapy in 4
patients and radiation in one patient. Six patients had
recurrent disease after surgery and the mean disease
free interval was 56.5 months. Three of the 6 patients
received chemotherapy treatment. Five of 11 (45.5%)
patients had coexistent double cancer. Two patients had
gastric cancer, and one patient each had prostate, blad-
der, and rectal cancer, respectively. Five patients died
due to a recurrence of lung cancer. Complete follow-up
data were available on all patients.
Histological type between the primary lesion and lymph
node metastasis
The prevalent histological differentiation of AD was
moderately differentiated (45%, 5/11), while the preva-
lent SQ was moderately differentiated in 82% (9/11;
Table 2). The two elements identified were either in
contiguous fields or intermingling, and the ratios
between the two yielded three groups. In 3 tumors, the
AD component exceeded the SQ component. In 7
tumors, the reverse was true. Only one case showed
both components present in roughly equal quantities.
Lymph node metastases were found in 6 cases (55%)
and were more frequent in cases with a larger SQ com-
ponent in the primary lesion (Table 3).
Relationship between ADSQ and clinicopathological
factors
When the clinicopathological factors were compared by
AD, the status of ADSQ did not significantly affect the
sex and coexistent double cancer. However, an ADSQ
was found more frequently in old age, advanced stage,
advanced T status, and N status. When the clinico-
pathological factors were compared by SQ, the status of
ADSQ did not significantly affect the age, pathological
stage, T status or N status. However, an ADSQ was
found more frequently in females and coexistent double
cancers (Table 4). ADSQ also showed a significant cor-
relation with coexistent double cancers (ADSQ vs. non-
ADSQ p = 0.03).
Influence of ADSQ on overall survival
A univariate analysis showed no significant prognostic
difference between the patients with old age, histological
type divided into ADSQ, coexistent double cancer, and
MPLC. Meanwhile males, advanced T, and N status
were associated with an unfavorable prognosis (Table 5).
The five-year survival of AD, SQ, and ADSQ was 71.4,
55.8, and 50.6%, respectively. A multivariate analysis
included such factors as sex, age, T status, N status, his-
tological type, coexistent double cancer, and MPLC.
Though, no significant prognostic difference was identi-
fied between the patients with regard to histological
type, coexistent double cancer, and MPLC, the prog-
nosis for patients with male sex, old age, advanced T,
and N status was significantly worse, compared with the
patients for counter features (Table 6).
Discussion
The classification of lung carcinoma into a small cell lung
carcinoma (SCLC) and NSCLC is highly reproducible.
However, there are few studies about ADSQ with anec-
dotal reports on the subtype of ADSQ. ADSQ of the lung
Table 2 Degree of histological differentiation for each
component










Table 3 Comparison of Histological type between the
primary lesion and lymph node metastasis
Primary lesion No of cases N0 lymph node metastasis
AD ADSQ SQ
AD > SQ 3 2 0 1* 0
AD = SQ 1 0 1 0 0
SQ > AD 7 3 1 1 2
Total 11 5 2 2 2
* Histological type of hilar and mediastinal lymph node metastasis was ADand
ADSQ, respectively.
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is a subset of pulmonary carcinomas, and comprises less
than 4% of lung carcinomas [4,6-8]. It is quite difficult to
diagnose ADSQ preoperatively [12]. In fact, only seven of
11 patients were diagnosed NSCLC as either AD and SQ.
Interestingly, the preoperative pathological diagnosis was
judged to the AD in case 1, nevertheless the preoperative
cytological diagnosis was SQ by washing and brushing
cytology under bronchoscopy. Physicians should there-
fore suspect ADSQ in cases where there is this type of
preoperative mixed diagnosis.
This study identified no significant prognostic differ-
ence was identified between the patients with ADSQ
and non-ADSQ. These findings are consistent with
Hsia’s data [4]. However, other researchers report the
highly aggressive behavior of ADSQ [6,7,12-14]. This
discrepancy might be attributed to three main factors.
The first is that the current study observed very few
patients with ADSQ. Due to the infrequent occurrence
of this disease, no series reported to date has been of
adequate size for a definitive statistical analysis. The sec-
ond possibility is a previous international discrepancy in
the pathological recording. At the present, Japanese lung
cancer society defines ADSQ as tumor composed of SQ
and AD components of at least 20% each [10]. However,
previous World Health Organization histological classifi-
cations did not refer to the ratio of these two compo-
nents and recent classification has required a minimum
Table 4 Relationships between the level of ADSQ and the clinicopathological characteristics in 601 lung cancer
patients
Characteristics Total ADSQ AD SQ P valuea
Total 601 11 403 187
Gender
Male 398 6 (54.5) 226 (56.1) 166 (88.8)
Female 203 5 (45.5) 177 (43.9) 21 (11.2) 0.9194/0.0011
Age (y)
<70 286 5 (45.5) 210 (52.1) 71 (38.0)
≥70 315 6 (54.5) 193 (47.9) 116 (62.0) 0.017/0.6198
Pathologic stage
I-II 460 5 (45.5) 338(83.8) 117 (62.6)
III-IV 141 6 (54.5) 65 (16.1) 70 (37.4) < 0.01/0.2567
pT
T1-2 521 6 (54.5) 375 (93.1) 140 (74.9)
T3-4 80 5 (45.5) 28 (6.9) 47 (25.1) < 0.0001/0.1367
PN
N0 411 5 (45.5) 313 (77.7) 93 (49.7)
N1-2 190 6 (54.5) 90 (22.3) 94 (52.2) 0.013/0.7564
Double ca
Yes 123 5 (45.5) 85 (21.1) 33 (17.6) 0.053/0.023
No 478 6 (54.5) 318 (78.9) 154 (82.3)
a The p value of former before slashdot was calculated by between ADSQ and AD. The p value of latter after slashdot was calculated by between ADSQ and SQ.
Table 5 Univariate analysis using a proportional hazard
model for the survival of the 799 lung cancer patients.
Univariate analysis
Variable 95% CI Hazard ratio P value
Gender
Female 1
Male 1.43-2.63 1.950 < 0.0001
Age (y)
<70 1
≥70 1.80-1.793 1.392 0.105
pT
T1-2 1
T3-4 1.86-3.27 2.46 < 0.0001
pN
N0 1
N1-2 2.25-3.73 2.90 < 0.0001
Histological type
Non- ADSQ 1
ADSQ 0.48-350 1.302 0.601
Double ca
No 1
Yes 0.61-1.14 0.833 0.253
MPLC
No 1
Yes 0.54-1.49 0.89 0.671
95% CI: 95% confidence interval.
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of 10% of each component. The third possibility may be
the discrepancy among the pathological diagnosis [15].
This is the first report to address the problem of coex-
istent double cancer with ADSQ. In general, the preva-
lence of coexistent double cancer for the patients with
lung cancer is about 10% of lung carcinomas [16]. Sur-
prisingly, almost half of all patients with ADSQ of the
lung were observed to have coexistent double cancer.
Some clinical experiences have been reported [17] based
on the concept of filed carcinogenesis in specific organ
system such as respiratory or gastrointestinal tract,
which are consistent with the current. Thus, behavior of
tumor with ADSQ might be amore aggressive than the
tumor with AD or SQ. It is necessary to suspect the
presence of double cancer not only in the medical
examination for the patients before treatment of ADSQ,
but also during the follow-up after a complete resection.
Carcinogenesis is a multi-step gene abnormality and
requires a certain amount of time to progress. ADSQ
was found more frequently in old age than AD in this
study suggesting that age is the one of the main risk fac-
tors for this type of cancer. Heterogeneity is frequent in
cancer and ADSQ is an atypical heterogeneous tumor
containing two distinct components of AD and SQ.
Therefore, the current findings, which show a high pre-
valence of coexistent double cancer, suggest the cancer
cells not only consist of mixture of AD and SQ, but also
show progression of carcinogenesis with specific
mechanisms in separate organs. The original histogen-
esis remains unclear. However, the biological impact is
very interesting because the squamous cell component
does not exist in the peripheral lung. Lymph node
metastases were more frequent in cases with a larger
SQ component in the primary lesion in this study.
Therefore characterization of ADSQ may be a first step
based on carcinogenesis to resolve the mystery of the
heterogeneity. The histogenesis of ADSQ includes some
possibilities including AD with squamous metaplasia,
collision tumor, high-grade mucoepidermoid carcinoma,
and bi-potential undifferentiated cell origin [18]. Niho et
al. showed that SQ and AD components showed identi-
cal monoclonal patterns, suggesting that the SQ and AD
components originate from the same cell [19]. Kanazawa
et al. also reported the clonal expansion in the carcino-
genic process by the monoclonal transition from SQ to
AD in ADSQ [20]. Therefore, the histogenesis of ADSQ
might represent a phase in ongoing differentiation from
a common cancer stem cell.
In conclusion, this current study demonstrated that
ADSQ is an unusual histological subtype of NSCLC and
approximately half of the patients with ADSQ had coex-
istent double cancer, thus suggesting that cancer cells in
ADSQ demonstrate progressive carcinogenesis with spe-
cific mechanisms.
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